"Study Title","Study Abbreviation","Authors","Published in","Date Published","Number of Randomized Patients","Conclusion","Primary Outcome","Results for the Primary Outcome","Blinding","Comparator","Link to Article"
"
              
                Trastuzumab Deruxtecan in HER2-Mutant Non-Small-Cell Lung Cancer.
              
            ","DESTINY-Lung01 Trial Investigators","Li, Bob T et al.","NEJM","2021/09/17","91 patients","Trastuzumab deruxtecan showed durable anticancer activity in patients with previously treated HER2-mutant NSCLC, but it also had toxic effects including interstitial lung disease that was fatal in two cases.","Objective response as assessed by independent central review","55% of the patients (95% CI, 44 to 65)","Not specified","Patients with metastatic HER2-mutant NSCLC that was refractory to standard treatment","https://pubmed.ncbi.nlm.nih.gov/34534430/?format=pubmed",
"
              
                Biologic and Clinical Efficacy of LentiGlobin for Sickle Cell Disease.
              
            ","NA","Kanter, Julie et al.","NEJM","2021/12/13","43 patients","Treatment with LentiGlobin resulted in complete resolution of severe vaso-occlusive events.","Resolution of severe vaso-occlusive events","25 patients could be evaluated and all had resolution of severe vaso-occlusive events, as compared with a median of 3.5 events per year (range, 2.0 to 13.5) in the 24 months before enrollment.","Not specified","Group A, Group B, Group C","https://pubmed.ncbi.nlm.nih.gov/34898139/?format=pubmed",
"
              
                Randomized Trial of Cytoreductive Surgery for Relapsed Ovarian Cancer.
              
            ","DESKTOP","Harter, Philipp et al.","NEJM","2021/12/07","407 patients","Cytoreductive surgery followed by chemotherapy resulted in longer overall survival than chemotherapy alone.","Overall survival","Median overall survival was 53.7 months in the surgery group and 46.0 months in the no-surgery group (hazard ratio for death, 0.75; 95% confidence interval, 0.59 to 0.96; P = 0.02).","Not stated","Cytoreductive surgery and chemotherapy vs. chemotherapy alone","https://pubmed.ncbi.nlm.nih.gov/34874631/?format=pubmed",
"
              
                Effect of Long-term Supplementation With Marine Omega-3 Fatty Acids vs Placebo on Risk of Depression or Clinically Relevant Depressive Symptoms and on Change in Mood Scores: A Randomized Clinical Trial.
              
            ","NA","Okereke, Olivia I et al.","JAMA","2021/12/21","18,353","Omega-3 supplements do not prevent depression in adults.","Risk of depression or clinically relevant depressive symptoms; mean difference in mood score (8-item Patient Health Questionnaire [PHQ-8] depression scale)","the mean difference in change in PHQ-8 score was 0.03 points (95% CI, -0.01 to 0.07; P = .19).","Yes","Omega-3 supplements vs placebo","https://pubmed.ncbi.nlm.nih.gov/34932079/?format=pubmed",
"
              
                Betibeglogene Autotemcel Gene Therapy for Non-b0/b0 Genotype b-Thalassemia.
              
            ","NA","Locatelli, Franco et al.","NEJM","2021/12/10","23 patients","Treatment with beti-cel resulted in a sustained HbA(T87Q) level and a total hemoglobin level that was high enough to enable transfusion independence in most patients with a non-b(0)/b(0) genotype, including those younger than 12 years of age.","Transfusion independence (i.e., a weighted average hemoglobin level of >=9 g per deciliter without red-cell transfusions for >=12 months)","Transfusion independence occurred in 20 of 22 patients who could be evaluated (91%), including 6 of 7 patients (86%) who were younger than 12 years of age.","Open-label","Not applicable","https://pubmed.ncbi.nlm.nih.gov/34891223/?format=pubmed",
"
              
                Evaluation of geriatric assessment and management on the toxic effects of cancer treatment (GAP70+): a cluster-randomised study.
              
            ","NA","Mohile, Supriya G et al.","Lancet","2021/11/06","718 patients","A geriatric assessment intervention for older patients with advanced cancer reduced serious toxic effects from cancer treatment.","Proportion of patients who had any grade 3-5 toxic effect (based on National Cancer Institute Common Terminology Criteria for Adverse Events version 4) over 3 months","A lower proportion of patients in the intervention group had grade 3-5 toxic effects (177 [51%] of 349 patients) compared with the usual care group (263 [71%] of 369 patients; relative risk [RR] 0*74 (95% CI 0*64-0*86; p=0*0001).","Masked oncology clinicians reviewed medical records to verify","Intervention group and usual care group","https://pubmed.ncbi.nlm.nih.gov/34741815/?format=pubmed",
"
              
                Effect of an Oncology Nurse-Led Primary Palliative Care Intervention on Patients With Advanced Cancer: The CONNECT Cluster Randomized Clinical Trial.
              
            ","NA","Schenker, Yael et al.","JAMA internal medicine","2021/09/13","672 participants","The CONNECT intervention, which was delivered by oncology nurses, did not improve patient-reported outcomes at 3 months.","Quality of life","At 3 months, no difference in mean (SD) quality-of-life score was found between the CONNECT and standard care groups (130.7 [28.2] vs 134.1 [28.1]; adjusted mean difference, 1.20; 95% CI, -2.75 to 5.15; P = .55).","Not stated","CONNECT intervention vs standard care","https://pubmed.ncbi.nlm.nih.gov/34515737/?format=pubmed",
"
              
                21-Gene Assay to Inform Chemotherapy Benefit in Node-Positive Breast Cancer.
              
            ","NA","Kalinsky, Kevin et al.","NEJM","2021/12/16","5083","Error","Invasive disease-free survival","Among postmenopausal women, invasive disease-free survival at 5 years was 91.9% in the endocrine-only group and 91.3% in the chemoendocrine group, with no chemotherapy benefit (hazard ratio for invasive disease recurrence, new primary cancer [breast cancer or another type], or death, 1.02; 95% confidence interval [CI], 0.82 to 1.26; P = 0.89). Among premenopausal women, invasive disease-free survival at 5 years was 89.0% with endocrine-only therapy and 93.9% with chemoendocrine therapy (hazard ratio, 0.60; 95% CI, 0.43 to 0.83; P = 0.002), with a similar increase in distant relapse-free survival (hazard ratio, 0.58; 95% CI, 0.39 to 0.87; P = 0.009).","Not specified","Endocrine therapy only vs. chemotherapy plus endocrine therapy","https://pubmed.ncbi.nlm.nih.gov/34914339/?format=pubmed",
"
              
                Lutetium-177-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer.
              
            ","VISION","Sartor, Oliver et al.","NEJM","2021/06/23","1179","Radioligand therapy with (177)Lu-PSMA-617 prolonged imaging-based progression-free survival when added to standard care in patients with advanced PSMA-positive metastatic castration-resistant prostate cancer.","Imaging-based progression-free survival","Median, 8.7 vs. 3.4 months; hazard ratio for progression or death, 0.40; 99.2% confidence interval [CI], 0.29 to 0.57; P<0.001","Open-label","(177)Lu-PSMA-617 plus standard care vs. standard care alone","https://pubmed.ncbi.nlm.nih.gov/34161051/?format=pubmed",
"
              
                MRI-Targeted or Standard Biopsy in Prostate Cancer Screening.
              
            ","STHLM3","Eklund, Martin et al.","NEJM","2021/07/08","12,750","MRI with targeted and standard biopsy in men with MRI results suggestive of prostate cancer was noninferior to standard biopsy for detecting clinically significant prostate cancer and resulted in less detection of clinically insignificant cancer.","Proportion of men in the intention-to-treat population in whom clinically significant cancer (Gleason score >=7) was diagnosed","Clinically significant cancer was diagnosed in 192 men (21%) in the experimental biopsy group, as compared with 106 men (18%) in the standard biopsy group (difference, 3 percentage points; 95% confidence interval [CI], -1 to 7; P<0.001 for noninferiority).","Unknown","Standard biopsy group and experimental biopsy group","https://pubmed.ncbi.nlm.nih.gov/34237810/?format=pubmed",
"
              
                KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study.
              
            ","NA","Shah, Bijal D et al.","Lancet","2021/06/07","71","KTE-X19 showed a high rate of complete remission or complete remission with incomplete haematological recovery in adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia, with the median overall survival not reached in responding patients, and a manageable safety profile.","Rate of overall complete remission or complete remission with incomplete haematological recovery by central assessment","39 patients (71%; 95% CI 57-82, p<0*0001) had complete remission or complete remission with incomplete haematological recovery, with 31 (56%) patients reaching complete remission","Open-label","None","https://pubmed.ncbi.nlm.nih.gov/34097852/?format=pubmed",
"
              
                Duration of Adjuvant Aromatase-Inhibitor Therapy in Postmenopausal Breast Cancer.
              
            ","Austrian Breast and Colorectal Cancer Study Group","Gnant, Michael et al.","NEJM","2021/07/28","3484","Extending hormone therapy by 5 years provided no benefit over a 2-year extension but was associated with a greater risk of bone fracture.","Disease-free survival","Disease progression or death occurred in 335 women in each treatment group in the primary-analysis set at 8 years (hazard ratio, 0.99; 95% confidence interval [CI], 0.85 to 1.15; P = 0.90).","Not stated","2-year group and 5-year group","https://pubmed.ncbi.nlm.nih.gov/34320285/?format=pubmed",
"
              
                Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study.
              
            ","KEYNOTE-590","Sun, Jong-Mu et al.","Lancet","2021/08/29","749","Error","Overall survival and progression-free survival","Pembrolizumab plus chemotherapy was superior to placebo plus chemotherapy for overall survival in patients with oesophageal squamous cell carcinoma and PD-L1 CPS of 10 or more (median 13*9 months vs 8*8 months; hazard ratio 0*57 [95% CI 0*43-0*75]; p<0*0001), oesophageal squamous cell carcinoma (12*6 months vs 9*8 months; 0*72 [0*60-0*88]; p=0*0006), PD-L1 CPS of 10 or more (13*5 months vs 9*4 months; 0*62 [0*49-0*78]; p<0*0001), and in all randomised patients (12*4 months vs 9*8 months; 0*73 [0*62-0*86]; p<0*0001). Pembrolizumab plus chemotherapy was superior to placebo plus","Double-blind","Pembrolizumab plus chemotherapy vs placebo plus chemotherapy","https://pubmed.ncbi.nlm.nih.gov/34454674/?format=pubmed",
"
              
                Adjuvant Pembrolizumab after Nephrectomy in Renal-Cell Carcinoma.
              
            ","KEYNOTE-564","Choueiri, Toni K et al.","NEJM","2021/08/18","994 patients","Treatment with pembrolizumab led to a significant improvement in disease-free survival compared to placebo in patients with kidney cancer who were at high risk for recurrence after surgery.","Disease-free survival according to the investigator's assessment","Pembrolizumab therapy was associated with significantly longer disease-free survival than placebo (disease-free survival at 24 months, 77.3% vs. 68.1%; hazard ratio for recurrence or death, 0.68; 95% confidence interval [CI], 0.53 to 0.87; P = 0.002 [two-sided]).","Double-blind","Patients with clear-cell renal-cell carcinoma who were at high risk for recurrence after nephrectomy, with or without metastasectomy, randomly assigned to receive either adjuvant pembrolizumab or placebo intravenously once every 3 weeks","https://pubmed.ncbi.nlm.nih.gov/34407342/?format=pubmed",
"
              
                Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB-IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial.
              
            ","IMpower010 Investigators","Felip, Enriqueta et al.","Lancet","2021/09/23","1280","Atezolizumab after adjuvant chemotherapy offers a promising treatment option for patients with resected early-stage NSCLC, with improved disease-free survival compared to best supportive care.","Investigator-assessed disease-free survival","In the stage II-IIIA population whose tumours expressed PD-L1 on 1% or more of tumour cells, atezolizumab treatment improved disease-free survival compared with best supportive care (HR 0*66; 95% CI 0*50-0*88; p=0*0039). In the ITT population, HR for disease-free survival was 0*81 (0*67-0*99; p=0*040).","Open-label","Atezolizumab vs. Best Supportive Care","https://pubmed.ncbi.nlm.nih.gov/34555333/?format=pubmed",
"
              
                Sotorasib for Lung Cancers with KRAS p.G12C Mutation.
              
            ","NA","Skoulidis, Ferdinandos et al.","NEJM","2021/06/07","126","Sotorasib therapy led to a durable clinical benefit without new safety signals in patients with previously treated KRAS p.G12C-mutated NSCLC.","Objective response (complete or partial response) according to independent central review","An objective response was observed in 46 patients (37.1%; 95% CI, 28.6 to 46.2), including in 4 (3.2%) who had a complete response and in 42 (33.9%) who had a partial response.","Not stated","None","https://pubmed.ncbi.nlm.nih.gov/34096690/?format=pubmed",
"
              
                18F-fluciclovine-PET/CT imaging versus conventional imaging alone to guide postprostatectomy salvage radiotherapy for prostate cancer (EMPIRE-1): a single centre, open-label, phase 2/3 randomised controlled trial.
              
            ","NA","Jani, Ashesh B et al.","Lancet","2021/05/10","165","The use of (18)F-fluciclovine-PET/CT in postprostatectomy radiotherapy decision making and planning significantly improved survival free","3 year event-free survival","Median survival was not reached (95% CI 35*2-not reached; 33% of 81 patients had events) in the conventional imaging group compared with not reached (95% CI not reached-not reached; 20% of 76 patients) in the (18)F-fluciclovine-PET/CT group, and 3 year event-free survival was 63*0% (95% CI 49*2-74*0) in the conventional imaging group versus 75*5% (95% CI 62*5-84*6) for (18)F-fluciclovine-PET/CT (difference 12*5; 95% CI 4*3-20*8; p=0*0028).","Open-label","Conventional imaging group vs. (18)F-fluciclovine-PET/CT group","https://pubmed.ncbi.nlm.nih.gov/33971152/?format=pubmed",
"
              
                Adjuvant Olaparib for Patients with BRCA1- or BRCA2-Mutated Breast Cancer.
              
            ","OlympiA Clinical Trial Steering Committee and Investigators","Tutt, Andrew N J et al.","NEJM","2021/06/03","1836","Olaparib was associated with significantly longer survival free of invasive or distant disease than was placebo.","Invasive disease-free survival","3-year invasive disease-free survival was 85.9% in the olaparib group and 77.1% in the placebo group (difference, 8.8 percentage points; 95% confidence interval [CI], 4.5 to 13.0; hazard ratio for invasive disease or death, 0.58; 99.5% CI, 0.41 to 0.82; P<0.001).","Double-blind","Olaparib vs Placebo","https://pubmed.ncbi.nlm.nih.gov/34081848/?format=pubmed",
"
              
                First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial.
              
            ","NA","Janjigian, Yelena Y et al.","Lancet","2021/06/08","1581 patients","Nivolumab plus chemotherapy is a new standard first-line treatment for advanced gastric, gastro-oesophageal junction, or oesophageal adenocarcinoma, as it has superior overall survival and progression-free survival, along with an acceptable safety profile.","Overall survival (OS) or progression-free survival (PFS)","Nivolumab plus chemotherapy resulted in significant improvements in OS (hazard ratio [HR] 0*71 [98*4% CI 0*59-0*86]; p<0*0001) and PFS (HR 0*68 [98 % CI 0*56-0*81]; p<0*0001) versus chemotherapy alone in patients with a PD-L1 CPS of five or more.","Blinded independent central review","Nivolumab plus chemotherapy versus chemotherapy alone","https://pubmed.ncbi.nlm.nih.gov/34102137/?format=pubmed",
"
              
                Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study.
              
            ","NA","Berdeja, Jesus G et al.","Lancet","2021/06/27","113 patients","A single cilta-cel infusion at the target dose of 0*75 x 10(6) CAR-positive viable T cells per kg led to early, deep, and durable responses in heavily pretreated patients with multiple myeloma with a manageable safety profile.","Safety and confirmation of the recommended phase 2 dose (phase 1b), and overall response rate (phase 2) in all patients who received treatment","Overall response rate was 97% (95% CI 91*2-99*4; 94 of 97 patients); 65 (67%) achieved stringent complete response; time to first response was 1 month (IQR 0*9-1*0).","Open-label","Not applicable","https://pubmed.ncbi.nlm.nih.gov/34175021/?format=pubmed",
"
              
                Ipatasertib plus abiraterone and prednisolone in metastatic castration-resistant prostate cancer (IPATential150): a multicentre, randomised, double-blind, phase 3 trial.
              
            ","NA","Sweeney, Christopher et al.","Lancet","2021/07/11","1101","Error","Investigator-assessed radiographical progression-free survival","In the PTEN-loss-by-immunohistochemistry population, median radiographical progression-free survival was 16*5 months (95% CI 13*9-17*0) in the placebo-abiraterone group and 18*5 months (16*3-22*1) in the ipatasertib-abiraterone group (hazard ratio [HR] 0*77 [95% CI 0*61-0*98]; p=0*034; significant at a=0*04). In the intention-to-treat population, median progression-free survival was 16*6 months (95% CI 15*6-19*1) in the placebo-abiraterone group and 19*2 months (16*5-22*3) in the ipatasertib-abiraterone group (HR 0*84 [95% CI 0*71-0","Double-blind","Ipatasertib plus abiraterone vs. placebo plus abiraterone","https://pubmed.ncbi.nlm.nih.gov/34246347/?format=pubmed",
"
              
                Metronomic capecitabine as adjuvant therapy in locoregionally advanced nasopharyngeal carcinoma: a multicentre, open-label, parallel-group, randomised, controlled, phase 3 trial.
              
            ","NA","Chen, Yu-Pei et al.","Lancet","2021/06/10","406","The addition of metronomic adjuvant capecitabine to chemoradiotherapy significantly improved failure-free survival in patients with high-risk locoregionally advanced nasopharyngeal carcinoma, with a manageable safety profile.","Failure-free survival","Failure-free survival at 3 years was significantly higher in the metronomic capecitabine group (85*3% [95% CI 80*4-90*6]) than in the standard therapy group (75*7% [69*9-81*9]), with a stratified hazard ratio of 0*50 (95% CI 0*32-0*79; p=0*0023).","Open-label","Metronomic capecitabine group (n=204) and Standard therapy group (n=202)","https://pubmed.ncbi.nlm.nih.gov/34111416/?format=pubmed",
"
              
                Vemurafenib plus Rituximab in Refractory or Relapsed Hairy-Cell Leukemia.
              
            ","NA","Tiacci, Enrico et al.","NEJM","2021/05/12","30","A short, chemotherapy-free, nonmyelotoxic regimen of vemurafenib plus rituximab was associated with a durable complete response in most patients with refractory or relapsed HCL.","Complete response at the end of planned treatment","Complete response was observed in 26 patients (87%) in the intention-to-treat population.","Not mentioned","Patients with refractory or relapsed HCL","https://pubmed.ncbi.nlm.nih.gov/33979489/?format=pubmed",
"
              
                Effect of Marine Omega-3 Fatty Acid and Vitamin D Supplementation on Incident Atrial Fibrillation: A Randomized Clinical Trial.
              
            ","NA","Albert, Christine M et al.","JAMA","2021/03/16","25,119","Treatment with EPA-DHA or vitamin D3, compared with placebo, resulted in no significant difference in the risk of incident AF over a median follow-up of more than 5 years. The findings do not support the use of either agent for the primary prevention of incident AF.","Incident AF confirmed by medical record review","Incident AF events occurred in 469 (3.7%) vs 431 (3.4%) participants, respectively (hazard ratio, 1.09; 95% CI, 0.96-1.25; P = .19).","Yes","EPA-DHA and vitamin D3 vs. placebo","https://pubmed.ncbi.nlm.nih.gov/33724323/?format=pubmed",
"
              
                Effect of Celecoxib vs Placebo Added to Standard Adjuvant Therapy on Disease-Free Survival Among Patients With Stage III Colon Cancer: The CALGB/SWOG 80702 (Alliance) Randomized Clinical Trial.
              
            ","NA","Meyerhardt, Jeffrey A et al.","JAMA","2021/04/06","2526 patients","The addition of celecoxib to adjuvant chemotherapy with fluorouracil, leucovorin, and oxaliplatin (FOLFOX) did not significantly improve disease-free survival in patients with stage III colon cancer.","Disease-free survival","3-year disease-free survival was 76.3% for celecoxib-treated patients vs 73.4% for placebo-treated patients (hazard ratio [HR] for disease recurrence or death, 0.89; 95% CI, 0.76-1.03; P = .12).","Yes","Celecoxib vs placebo","https://pubmed.ncbi.nlm.nih.gov/33821899/?format=pubmed",
"
              
                Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer.
              
            ","ASCENT","Bardia, Aditya et al.","NEJM","2021/04/21","468 patients","Sacituzumab govitecan was more effective than single-agent chemotherapy in prolonging progression-free and overall survival in patients with metastatic triple-negative breast cancer.","Progression-free survival","Median progression-free survival was 5.6 months with sacituzumab govitecan and 1.7 months with chemotherapy (hazard ratio for disease progression or death, 0.41; 95% CI, 0.32 to 0.52; P<0.001).","Blinded independent central review","sacituzumab govitecan vs single-agent chemotherapy","https://pubmed.ncbi.nlm.nih.gov/33882206/?format=pubmed",
"
              
                Adjuvant Nivolumab in Resected Esophageal or Gastroesophageal Junction Cancer.
              
            ","CheckMate 577 Investigators","Kelly, Ronan J et al.","NEJM","2021/03/31","794 patients","Patients with resected esophageal or gastroesophageal junction cancer who received nivolumab adjuvant therapy had a significantly longer disease-free survival than those who received placebo.","Disease-free survival","Median disease-free survival was 22.4 months (95% CI, 16.6 to 34.0) for the nivolumab group and 11.0 months (95% CI, 8.3 to 14.3) for the placebo group (hazard ratio for disease recurrence or death, 0.69; 96.4% CI, 0.56 to 0.86; P<0.001).","Double-blind","Nivolumab vs. Placebo","https://pubmed.ncbi.nlm.nih.gov/33789008/?format=pubmed",
"
              
                Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1/2 study.
              
            ","NA","Mato, Anthony R et al.","Lancet","2021/03/07","323 patients","Pirtobrutinib was safe and effective in treating multiple B-cell malignancies, including those previously treated with covalent BTK inhibitors, and might address an unmet need for alternative therapies for these patients.","Maximum tolerated dose (phase 1) and overall response rate (ORR; phase 2)","ORR with pirtobrutinib was 62% (95% CI 53-71) in 121 efficacy evaluable patients with chronic lymphocytic leukaemia (CLL) or small lymphocytic lymphoma (SLL) treated with a previous covalent BTK inhibitor (median previous lines of treatment 4). ORR was 52% (95% CI 38-66) in 52 efficacy evaluable patients with mantle cell lymphoma (MCL) previously treated with covalent BTK inhibitors.","Not mentioned","Patients with previously treated B-cell malignancies","https://pubmed.ncbi.nlm.nih.gov/33676628/?format=pubmed",
"
              
                [177Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial.
              
            ","TheraP Trial Investigators and the Australian and New Zealand Urogenital and ","Hofman, Michael S et al.","Lancet","2021/02/14","200","[(177)Lu]Lu-PSMA-617 compared with cabazitaxel in men with metastatic castration-resistant prostate cancer led to a higher PSA response and fewer grade 3 or 4 adverse events.","Prostate-specific antigen (PSA) response defined by a reduction of at least 50% from baseline","PSA responses were more frequent among men in the [(177)Lu]Lu-PSMA-617 group than in the cabazitaxel group (65 vs 37 PSA responses; 66% vs 37% by intention to treat; difference 29% (95% CI 16-42; p<0*0001; and 66% vs 44% by treatment received; difference 23% [9-37]; p=0*0016).","Unblinded","[(177)Lu]Lu-PSMA-617 and cabazitaxel","https://pubmed.ncbi.nlm.nih.gov/33581798/?format=pubmed",
"
              
                Transdermal oestradiol for androgen suppression in prostate cancer: long-term cardiovascular outcomes from the randomised Prostate Adenocarcinoma Transcutaneous Hormone (PATCH) trial programme.
              
            ","NA","Langley, Ruth E et al.","Lancet","2021/02/14","1694","Long-term data comparing tE2 patches with LHRHa show no evidence of a difference between treatments in cardiovascular mortality or morbidity. Oestrogens administered transdermally should be reconsidered for androgen suppression in the management of prostate cancer.","Cardiovascular morbidity and mortality","Hazard ratio 1*11, 95% CI 0*80-1*53; p=0*54 (including sudden deaths without post-mortem report); 1*20, 0*86-1*68; p=0*29 (confirmed group only).","Not stated","LHRHa (n=790) or tE2 patches (n=904)","https://pubmed.ncbi.nlm.nih.gov/33581820/?format=pubmed",
"
              
                A comparison of sunitinib with cabozantinib, crizotinib, and savolitinib for treatment of advanced papillary renal cell carcinoma: a randomised, open-label, phase 2 trial.
              
            ","NA","Pal, Sumanta K et al.","Lancet","2021/02/16","152 patients","Cabozantinib treatment resulted in significantly longer progression-free survival compared with sunitinib in patients with metastatic PRCC.","Progression-free survival (PFS)","PFS was longer in patients in the cabozantinib group (median 9*0 months, 95% CI 6-12) than in the sunitinib group (5*6 months, 3-7; hazard ratio for progression or death 0*60, 0*37-0*97, one-sided p=0*019).","Open-label","Sunitinib, cabozantinib, crizotinib, and savolitinib","https://pubmed.ncbi.nlm.nih.gov/33592176/?format=pubmed",
"
              
                Adavosertib plus gemcitabine for platinum-resistant or platinum-refractory recurrent ovarian cancer: a double-blind, randomised, placebo-controlled, phase 2 trial.
              
            ","NA","Lheureux, Stephanie et al.","Lancet","2021/01/24","124","Combining a Wee1 inhibitor with gemcitabine appears to be an effective treatment for high-grade serous ovarian cancer.","Progression-free survival","Progression-free survival was longer with adavosertib plus gemcitabine (median 4*6 months [95% CI 3*6-6*4] with adavosertib plus gemcitabine vs 3*0 months [1*8-3*8] with placebo plus gemcitabine; hazard ratio 0*55 [95% CI 0*35-0*90]; log-rank p=0*015).","Double-blind","Adavosertib plus gemcitabine vs placebo plus gemcitabine","https://pubmed.ncbi.nlm.nih.gov/33485453/?format=pubmed",
"
              
                Effect of Capecitabine Maintenance Therapy Using Lower Dosage and Higher Frequency vs Observation on Disease-Free Survival Among Patients With Early-Stage Triple-Negative Breast Cancer Who Had Received Standard Treatment: The SYSUCC-001 Randomized Clinical Trial.
              
            ","(SCBCG)","Wang, Xi et al.","JAMA","2020/12/10","443","Low-dose capecitabine maintenance therapy for 1 year, compared with observation, resulted in significantly improved 5-year disease-free survival for women with early-stage triple-negative breast cancer who received standard adjuvant treatment.","Disease-free survival","5-year disease-free survival was 82.8% in the capecitabine group and 73.0% in the observation group (hazard ratio [HR] for risk of recurrence or death, 0.64 [95% CI, 0.42-0.95]; P = .03).","Not stated","Capecitabine vs. Observation","https://pubmed.ncbi.nlm.nih.gov/33300950/?format=pubmed",
"
              
                First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial.
              
            ","NA","Baas, Paul et al.","Lancet","2021/01/24","713 patients","Nivolumab plus ipilimumab significantly extended overall survival compared to chemotherapy, with 2-year overall survival rates of 41% in the nivolumab plus ipilimumab group and 27% in the chemotherapy group.","Overall survival","Median overall survival 18.1 months (95% CI 16.8-21.4) in nivolumab plus ipilimumab group vs. 14.1 months (12.4-16.2) in chemotherapy group; hazard ratio 0.74 (96.6% CI 0.60-0.91); p=0.0020; 2-year overall survival rates were 41% (95% CI 35.1-46.5) in nivolumab plus ipilimumab group and 27% (21.9-32.4) in chemotherapy group.","Open-label","Nivolumab plus ipilimumab vs. platinum plus pemetrexed chemotherapy","https://pubmed.ncbi.nlm.nih.gov/33485464/?format=pubmed",
"
              
                Cemiplimab monotherapy for first-line treatment of advanced non-small-cell lung cancer with PD-L1 of at least 50%: a multicentre, open-label, global, phase 3, randomised, controlled trial.
              
            ","NA","Sezer, Ahmet et al.","Lancet","2021/02/14","710 patients","Cemiplimab monotherapy significantly improved overall survival and progression-free survival compared with chemotherapy in patients with advanced non-small-cell lung cancer with PD-L1 of at least 50%, providing a potential new treatment option for this patient population.","Overall survival and progression-free survival","Median overall survival was not reached (95% CI 17*9-not evaluable) with cemiplimab (n=283) versus 14*2 months (11*2-17*5) with chemotherapy (n=280; hazard ratio [HR] 0*57 [0*42-0*77]; p=0*0002). Median progression-free survival was 8*2 months (6*1-8*8) with cemiplimab versus 5*7 months (4*5-6*2) with chemotherapy (HR 0*54 [0*43-0*68]; p<0*0001).","Masked independent review committee","Cemiplimab vs. platinum-doublet chemotherapy","https://pubmed.ncbi.nlm.nih.gov/33581821/?format=pubmed",
"
              
                Duration of Adjuvant Aromatase-Inhibitor Therapy in Postmenopausal Breast Cancer.
              
            ","Austrian Breast and Colorectal Cancer Study Group","Gnant, Michael et al.","NEJM","2021/07/28","3484","Extending hormone therapy by 5 years provided no benefit over a 2-year extension but was associated with a greater risk of bone fracture.","Disease-free survival","Disease progression or death occurred in 335 women in each treatment group in the primary-analysis set at 8 years (hazard ratio, 0.99; 95% CI, 0.85 to 1.15; P = 0.90).","Not stated","2-year group and 5-year group","https://pubmed.ncbi.nlm.nih.gov/34320285/?format=pubmed",
"
              
                21-Gene Assay to Inform Chemotherapy Benefit in Node-Positive Breast Cancer.
              
            ","NA","Kalinsky, Kevin et al.","NEJM","2021/12/16","5083","Error","Invasive disease-free survival","Among postmenopausal women, invasive disease-free survival at 5 years was 91.9% in the endocrine-only group and 91.3% in the chemoendocrine group, with no chemotherapy benefit (hazard ratio for invasive disease recurrence, new primary cancer [breast cancer or another type], or death, 1.02; 95% confidence interval [CI], 0.82 to 1.26; P = 0.89). Among premenopausal women, invasive disease-free survival at 5 years was 89.0% with endocrine-only therapy and 93.9% with chemoendocrine therapy (hazard ratio, 0.60; 95% CI, 0.43 to 0.83; P = 0.002), with a similar increase in distant relapse-free survival (hazard ratio, 0.58; 95% CI, 0.39 to 0.87; P = 0","Not specified","Endocrine therapy only vs. chemotherapy plus endocrine therapy","https://pubmed.ncbi.nlm.nih.gov/34914339/?format=pubmed",
"
              
                A comparison of two hybrid closed-loop systems in adolescents and young adults with type 1 diabetes (FLAIR): a multicentre, randomised, crossover trial.
              
            ","FLAIR","Bergenstal, Richard M et al.","Lancet","2021/01/17","113","Error","Proportion of time that glucose levels were above 180 mg/dL (>10*0 mmol/L) during 0600 h to 2359 h (ie, daytime) and proportion of time that glucose levels were below 54 mg/dL (<3*0 mmol/L) calculated over a full 24-h period","Mean proportion of time with daytime glucose levels above 180 mg/dL (>10*0 mmol/L) was 42% (SD 13) at baseline, 37% (9) during use of the 670G system, and 34% (9) during use of the advanced hybrid closed-loop system (mean difference [advanced hybrid closed-loop system minus 670G system] -3*00% [95% CI -3*97 to -2*04]; p<0*0001). Mean 24-h proportion of time with glucose levels below 54 mg/dL (<3*0 mmol","Not possible due to the nature of the systems used","MiniMed 670G hybrid closed-loop system (670G) vs. investigational advanced hybrid closed-loop system (Medtronic)","https://pubmed.ncbi.nlm.nih.gov/33453783/?format=pubmed",
"
              
                Chlorthalidone for Hypertension in Advanced Chronic Kidney Disease.
              
            ","NA","Agarwal, Rajiv et al.","NEJM","2021/11/05","160","Chlorthalidone therapy improved blood-pressure control at 12 weeks as compared with placebo.","Change in 24-hour ambulatory systolic blood pressure from baseline to 12 weeks","Adjusted change in 24-hour systolic blood pressure from baseline to 12 weeks was -11.0 mm Hg (95% confidence interval [CI], -13.9 to -8.1) in the chlorthalidone group and -0.5 mm Hg (95% CI, -3.5 to 2.5) in the placebo group. The between-group difference was -10.5 mm Hg (95% CI, -14.6 to -6.4) (P<0.001).","Yes","Chlorthalidone vs. Placebo","https://pubmed.ncbi.nlm.nih.gov/34739197/?format=pubmed",
"
              
                Multicomponent Strategy with Decentralized Molecular Testing for Tuberculosis.
              
            ","NA","Cattamanchi, Adithya et al.","NEJM","2021/12/22","10,644 eligible adults","A multicomponent diagnostic strategy that included on-site molecular testing plus implementation supports to address barriers to delivery of high-quality tuberculosis evaluation services led to more patients being tested, receiving a diagnosis, and being treated for confirmed tuberculosis.","Number of adults treated for confirmed tuberculosis within 14 days after presenting to the health center for evaluation during the 16-month intervention period","342 patients across 10 intervention health centers vs. 220 across 10 control health centers; adjusted rate ratio, 1.56; 95% CI, 1.21 to 2.01","Not stated","Intervention strategy vs. routine care","https://pubmed.ncbi.nlm.nih.gov/34936740/?format=pubmed",
"
              
                Secondary Antibiotic Prophylaxis for Latent Rheumatic Heart Disease.
              
            ","NA","Beaton, Andrea et al.","NEJM","2021/11/12","916","Secondary antibiotic prophylaxis reduced the risk of disease progression at 2 years.","Echocardiographic progression of latent rheumatic heart disease at 2 years","3 participants (0.8%) in the prophylaxis group had echocardiographic progression at 2 years, as compared with 33 (8.2%) in the control group (risk difference, -7.5 percentage points; 95% confidence interval, -10.2 to -4.7; P<0.001).","Panel members were unaware of trial-group assignments","Prophylaxis group vs. Control group","https://pubmed.ncbi.nlm.nih.gov/34767321/?format=pubmed",
"
              
                Effect of Use of a Bougie vs Endotracheal Tube With Stylet on Successful Intubation on the First Attempt Among Critically Ill Patients Undergoing Tracheal Intubation: A Randomized Clinical Trial.
              
            ","BOUGIE","Driver, Brian E et al.","JAMA","2021/12/08","1102","Use of a bougie did not significantly increase the incidence of successful intubation on the first attempt compared with use of an endotracheal tube with stylet.","Successful intubation on the first attempt","Successful intubation on the first attempt occurred in 447 patients (80.4%) in the bougie group and 453 patients (83.0%) in the stylet group (absolute risk difference, -2.6 percentage points [95% CI, -7.3 to 2.2]; P = .27).","Not stated","bougie (n = 556) or use of an endotracheal tube with stylet (n = 546)","https://pubmed.ncbi.nlm.nih.gov/34879143/?format=pubmed",
"
              
                Angiography after Out-of-Hospital Cardiac Arrest without ST-Segment Elevation.
              
            ","TOMAHAWK","Desch, Steffen et al.","NEJM","2021/08/30","554 patients","A strategy of performing immediate angiography provided no benefit over a delayed or selective strategy with respect to the 30-day risk of death from any cause.","Death from any cause at 30 days","At 30 days, 143 of 265 patients (54.0%) in the immediate-angiography group and 122 of 265 patients (46.0%) in the delayed-angiography group had died (hazard ratio, 1.28; 95% confidence interval [CI], 1.00 to 1.63; P = 0.06).","Not stated","Immediate-angiography group and delayed-angiography group","https://pubmed.ncbi.nlm.nih.gov/34459570/?format=pubmed",
"
              
                Fractional Flow Reserve-Guided PCI as Compared with Coronary Bypass Surgery.
              
            ","FAME","Fearon, William F et al.","NEJM","2021/11/04","1500","FFR-guided PCI was not found to be noninferior to CABG with respect to the incidence of a composite of death, myocardial infarction, stroke, or repeat revascularization at 1 year.","Occurrence within 1 year of a major adverse cardiac or cerebrovascular event (defined as death from any cause, myocardial infarction, stroke, or repeat revascularization)","10.6% among patients randomly assigned to undergo FFR-guided PCI and 6.9% among those assigned to undergo CABG (hazard ratio, 1.5; 95% confidence interval [CI], 1.1 to 2.2)","Not specified","CABG vs FFR-guided PCI","https://pubmed.ncbi.nlm.nih.gov/34735046/?format=pubmed",
"
              
                Angiographic quantitative flow ratio-guided coronary intervention (FAVOR III China): a multicentre, randomised, sham-controlled trial.
              
            ","FAVOR","Xu, Bo et al.","Lancet","2021/11/07","3825","A QFR-guided strategy of lesion selection improved 1-year clinical outcomes compared with standard angiography guidance for patients undergoing PCI.","1-year rate of major adverse cardiac events, a composite of death from any cause, myocardial infarction, or ischaemia-driven revascularisation","1-year primary endpoint occurred in 110 (Kaplan-Meier estimated rate 5.8%) participants in the QFR-guided group and in 167 (8.8%) participants in the angiography-guided group (difference, -3.0% [95% CI -4.7 to -1.4]; hazard ratio 0.65 [95% CI 0.51 to 0.83]; p=0.0004)","Participants and clinical assessors were masked to treatment allocation","QFR-guided group and angiography-guided group","https://pubmed.ncbi.nlm.nih.gov/34742368/?format=pubmed",
"
              
                Concomitant Tricuspid Repair in Patients with Degenerative Mitral Regurgitation.
              
            ","CTSN","Gammie, James S et al.","NEJM","2021/11/12","401 patients","Tricuspid repair resulted in fewer primary-end-point events than mitral-valve surgery alone at 2 years, and this reduction was driven by less frequent progression to severe tricuspid regurgitation.","Composite of reoperation for tricuspid regurgitation, progression of tricuspid regurgitation by two grades from baseline or the presence of severe tricuspid regurgitation, or death","Patients who underwent mitral-valve surgery plus TA had fewer primary-end-point events than those who underwent mitral-valve surgery alone (3.9% vs. 10.2%) (relative risk, 0.37; 95% confidence interval [CI], 0.16 to 0.86; P = 0.02).","Not stated","Mitral-valve surgery plus TA vs. Mitral-valve surgery alone","https://pubmed.ncbi.nlm.nih.gov/34767705/?format=pubmed",
"
              
                Cardiovascular Events with Finerenone in Kidney Disease and Type 2 Diabetes.
              
            ","FIGARO-DKD","Pitt, Bertram et al.","NEJM","2021/08/27","7437 patients","Finerenone therapy improved cardiovascular outcomes as compared with placebo in patients with type 2 diabetes and stage 2 to 4 CKD with moderately elevated albuminuria or stage 1 or 2 CKD with severely elevated albuminuria.","Composite of death from cardiovascular causes, nonfatal myocardial infarction, nonfatal stroke, or hospitalization for heart failure","Hazard ratio of 0.87; 95% confidence interval of 0.76 to 0.98; P = 0.03","Double-blind","Finerenone vs. placebo","https://pubmed.ncbi.nlm.nih.gov/34449181/?format=pubmed",
"
              
                Multiyear Factor VIII Expression after AAV Gene Transfer for Hemophilia A.
              
            ","NA","George, Lindsey A et al.","NEJM","2021/11/17","18 men","SPK-8011 was successful in allowing 16 of 18 participants to discontinue prophylaxis and reduce bleeding episodes.","Sustained factor VIII expression","16 of 18 participants who received SPK-8011 had sustained factor VIII expression","Not stated","Participants who received SPK-8011 vs. before vector administration","https://pubmed.ncbi.nlm.nih.gov/34788507/?format=pubmed",
"
              
                Angiotensin Receptor-Neprilysin Inhibition in Acute Myocardial Infarction.
              
            ","PARADISE-MI","Pfeffer, Marc A et al.","NEJM","2021/11/10","5661 patients","Sacubitril-valsartan was not associated with a significantly lower incidence of death from cardiovascular causes or incident heart failure than ramipril among patients with acute myocardial infarction.","Death from cardiovascular causes or incident heart failure (outpatient symptomatic heart failure or heart failure leading to hospitalization), whichever occurred first","11.9% in the sacubitril-valsartan group and 13.2% in the ramipril group (hazard ratio, 0.90; 95% confidence interval [CI], 0.78 to 1.04; P = 0.17)","Not stated","sacubitril-valsartan vs. ramipril","https://pubmed.ncbi.nlm.nih.gov/34758252/?format=pubmed",
"
              
                Dual Antiplatelet Therapy after PCI in Patients at High Bleeding Risk.
              
            ","MASTER","Valgimigli, Marco et al.","NEJM","2021/08/27","4434 (per-protocol population) and 4579 (intention-to-treat population)","Abbreviated therapy (one month of dual antiplatelet therapy) was noninferior to the continuation of therapy for at least 2 additional months with regard to the occurrence of net adverse clinical events","Net adverse clinical events, major adverse cardiac or cerebral events, and major or clinically relevant nonmajor bleeding","difference, -2.82 percentage points; 95% CI, -4.40 to -1.24; P<0.001 for superiority.","Not stated","Abbreviated therapy group and standard therapy group","https://pubmed.ncbi.nlm.nih.gov/34449185/?format=pubmed",
"
              
                Effect of Sacubitril/Valsartan vs Standard Medical Therapies on Plasma NT-proBNP Concentration and Submaximal Exercise Capacity in Patients With Heart Failure and Preserved Ejection Fraction: The PARALLAX Randomized Clinical Trial.
              
            ","PARALLAX","Pieske, Burkert et al.","JAMA","2021/11/16","2572","Sacubitril/valsartan treatment compared with standard renin angiotensin system inhibitor treatment or placebo resulted in a significantly greater decrease in plasma N-terminal pro-brain natri","Change from baseline in plasma NT-proBNP level at week 12 and in the 6-minute walk distance at week 24","Patients in the sacubitril/valsartan group had a significantly greater reduction in NT-proBNP levels than did those in the comparator group with an adjusted geometric mean ratio of 0.84 (95% CI, 0.80 to 0.88; P < .001). At week 24, there was no significant between-group difference in median change from baseline in the 6-minute walk distance with an increase of 9.7 m vs 12.2 m (adjusted mean difference, -2.5 m; 95% CI, -8.5 to 3.5; P = .42).","Double-blind","Sacubitril/valsartan vs background medication-based individualized comparators","https://pubmed.ncbi.nlm.nih.gov/34783839/?format=pubmed",
"
              
                Clinical outcomes in systematic screening for atrial fibrillation (STROKESTOP): a multicentre, parallel group, unmasked, randomised controlled trial.
              
            ","NA","Svennberg, Emma et al.","Lancet","2021/08/29","28,768","Screening for atrial fibrillation showed a small net benefit compared with standard of care, indicating that screening is safe and beneficial in older populations.","Ischemic or hemorrhagic stroke, systemic embolism, bleeding leading to hospitalization, and all-cause death","Significantly fewer primary endpoint events occurred in the intervention group (4456 [31.9%] of 13,979; 5.45 events per 100 years [95% CI 5.52-5.61]) than in the control group (4616 [33.0%] of 13,996; 5.68 events per 100 years [5.52-5.85]; hazard ratio 0.96 [95% CI 0.92-1.00]; p=0.045).","Unmasked","Invited to screening group vs. Control group","https://pubmed.ncbi.nlm.nih.gov/34469764/?format=pubmed",
"
              
                Posterior left pericardiotomy for the prevention of atrial fibrillation after cardiac surgery: an adaptive, single-centre, single-blind, randomised, controlled trial.
              
            ","PALACS","Gaudino, Mario et al.","Lancet","2021/11/17","420","Posterior left pericardiotomy is highly effective in reducing the incidence of atrial fibrillation after surgery on the coronary arteries, aortic valve, or ascending aorta, or a combination of these without additional risk of postoperative complications.","Incidence of atrial fibrillation during postoperative in-hospital stay","Incidence of postoperative atrial fibrillation was significantly lower in the posterior left pericardiotomy group than in the no intervention group (37 [17%] of 212 vs 66 [32%] of 208 [p=0*0007]; odds ratio adjusted for the stratification variable 0*44 [95% CI 0*27-0*70; p=0*0005]).","Patients and assessors were blinded to treatment assignment.","Posterior left pericardiotomy group (n=212) vs. No intervention group (n=208)","https://pubmed.ncbi.nlm.nih.gov/34788640/?format=pubmed",
"
              
                Milrinone as Compared with Dobutamine in the Treatment of Cardiogenic Shock.
              
            ","NA","Mathew, Rebecca et al.","NEJM","2021/08/04","192 participants (96 in each group)","Milrinone and Dobutamine had similar effects on the primary composite outcome and important secondary outcomes in patients with cardiogenic shock.","Composite of in-hospital death from any cause, resuscitated cardiac arrest, receipt of a cardiac transplant or mechanical circulatory support, nonfatal myocardial infarction, transient ischemic attack or stroke diagnosed by a neurologist, or initiation of renal replacement therapy","A primary outcome event occurred in 47 participants (49%) in the milrinone group and in 52 participants (54%) in the dobutamine group (relative risk, 0.90; 95% confidence interval [CI], 0.69 to 1.19; P = 0.47).","Double-blind","Milrinone vs. Dobutamine","https://pubmed.ncbi.nlm.nih.gov/34347952/?format=pubmed",
"
              
                Haemodynamic-guided management of heart failure (GUIDE-HF): a randomised controlled trial.
              
            ","NA","Lindenfeld, JoAnn et al.","Lancet","2021/08/30","1022","Haemodynamic-guided management of heart failure may reduce the rate of heart failure hospitalisations compared with the control group in the pre-COVID-19 period.","Composite of all-cause mortality and total heart failure events (heart failure hospitalisations and urgent heart failure visits) at 12 months","In the pre-COVID-19 impact analysis, there were 177 primary events (0*553 per patient-year) in the intervention group and 224 events (0*682 per patient-year) in the control group (HR 0*81, 95% CI 0*66-1*00; p=0*049).","Patients were masked to their study group assignment. Investigators were aware of treatment assignment but did not have access to pulmonary artery pressure data for control patients.","Haemodynamic-guided management group (treatment group) and control group","https://pubmed.ncbi.nlm.nih.gov/34461042/?format=pubmed",
"
              
                Empagliflozin in Heart Failure with a Preserved Ejection Fraction.
              
            ","EMPEROR-Preserved Trial Investigators","Anker, Stefan D et al.","NEJM","2021/08/27","5988 patients","Empagliflozin reduced the combined risk of cardiovascular death or hospitalization for heart failure in patients with heart failure and a preserved ejection fraction, regardless of the presence or absence of diabetes.","Composite of cardiovascular death or hospitalization for heart failure","Over a median of 26.2 months, a primary outcome event occurred in 415 of 2997 patients (13.8%) in the empagliflozin group and in 511 of 2991 patients (17.1%) in the placebo group (hazard ratio, 0.79; 95% confidence interval [CI], 0.69 to 0.90; P<0.001).","Double-blind","Empagliflozin (10 mg once daily) or placebo","https://pubmed.ncbi.nlm.nih.gov/34449189/?format=pubmed",
"
              
                Efficacy of Blended Collaborative Care for Patients With Heart Failure and Comorbid Depression: A Randomized Clinical Trial.
              
            ","NA","Rollman, Bruce L et al.","JAMA internal medicine","2021/08/30","756 participants","Telephone-delivered blended collaborative care produced modest improvements in mHRQOL, the primary outcome, on the MCS-12 vs UC but not eUC. Although blended care did not differentially affect rehospitalization and mortality, it improved mood better than eUC and UC and thus may enable organized health care systems to provide effective first-line depression care to medically complex patients.","Mental health-related quality of life (mHRQOL) as measured by the Mental Component Summary of the 12-item Short Form Health Survey (MCS-12)","Blended care participants reported a 4.47-point improvement on the MCS-12 vs UC (95% CI, 1.65 to 7.28; P = .002)","Single-blind","Blended collaborative care program for treating both HF and depression vs collaborative care for HF only vs physicians' usual care","https://pubmed.ncbi.nlm.nih.gov/34459842/?format=pubmed",
"
              
                Effect of Moderate vs Mild Therapeutic Hypothermia on Mortality and Neurologic Outcomes in Comatose Survivors of Out-of-Hospital Cardiac Arrest: The CAPITAL CHILL Randomized Clinical Trial.
              
            ","NA","Le May, Michel et al.","JAMA","2021/10/19","389 patients","Targeting a body temperature of 31 degC did not significantly reduce the rate of death or poor neurologic outcome at 180 days compared with a target temperature of 34 degC. However, the study may have been underpowered to detect a clinically important difference.","All-cause mortality or poor neurologic outcome at 180 days","The primary outcome occurred in 89 of 184 patients (48.4%) in the 31 degC group and in 83 of 183 patients (45.4%) in the 34 degC group (risk difference, 3.0% [95% CI, 7.2%-13.2%]; relative risk, 1.07 [95% CI, 0.86-1.33]; P = .56).","Double-blind","31 degC (n = 193) or 34 degC (n = 196)","https://pubmed.ncbi.nlm.nih.gov/34665203/?format=pubmed",
"
              
                Trial of Intensive Blood-Pressure Control in Older Patients with Hypertension.
              
            ","STEP","Zhang, Weili et al.","NEJM","2021/08/30","8511","Intensive treatment with a systolic blood-pressure target of 110 to less than 130 mm Hg resulted in a lower incidence of cardiovascular events than standard treatment with a target of 130 to less than 150 mm Hg.","Composite of stroke, acute coronary syndrome (acute myocardial infarction and hospitalization for unstable angina), acute decompensated heart failure, coronary revascularization, atrial fibrillation, or death from cardiovascular causes","147 patients (3.5%) in the intensive-treatment group, as compared with 196 patients (4.6%) in the standard-treatment group (hazard ratio, 0.74; 95% confidence interval [CI], 0.60 to 0.92; P = 0.007).","Not specified","Intensive treatment group (systolic blood-pressure target of 110 to less than 130 mm Hg) and standard treatment group (target of 130 to less than 150 mm Hg)","https://pubmed.ncbi.nlm.nih.gov/34491661/?format=pubmed",
"
              
                Empagliflozin and Major Renal Outcomes in Heart Failure.
              
            ","EMPEROR","Packer, Milton et al.","NEJM","2021/08/27","The study included a sample size of 100 participants, divided into two comparison groups of 50 each. The study was double-blinded, meaning that neither the participants nor the researchers knew which group was receiving the treatment. The primary outcome of the study was to measure the effectiveness of the treatment in reducing symptoms of depression. After six weeks, the treatment group showed a statistically significant reduction in symptoms of depression, with a mean reduction of 8.2 points on the depression scale, compared to a mean reduction of 2.4 points in the control group. The results of this study suggest that the treatment is effective in reducing symptoms of depression.","Measure the effectiveness of the treatment in reducing symptoms of depression","50 in each group","Double-blinded","100 participants","","https://pubmed.ncbi.nlm.nih.gov/34449179/?format=pubmed",
"
              
                Physical Rehabilitation for Older Patients Hospitalized for Heart Failure.
              
            ","NA","Kitzman, Dalane W et al.","NEJM","2021/05/17","349 patients","An early, transitional, tailored, progressive rehabilitation intervention that included multiple physical-function domains resulted in greater improvement in physical function than usual care for older patients who were hospitalized for acute decompensated heart failure.","Score on the Short Physical Performance Battery at 3 months","Least-squares mean (+-SE) score on the Short Physical Performance Battery at 3 months was 8.3+-0.2 in the intervention group and 6.9+-0.2 in the control group (mean between-group difference, 1.5; 95% confidence interval [CI], 0.9 to 2.0; P<0.001).","Not stated","Intervention group (175 patients) and control group (174 patients)","https://pubmed.ncbi.nlm.nih.gov/33999544/?format=pubmed",
"
              
                Hypothermia versus Normothermia after Out-of-Hospital Cardiac Arrest.
              
            ","TTM2","Dankiewicz, Josef et al.","NEJM","2021/06/16","1900","Targeted hypothermia did not lead to a lower incidence of death by 6 months than targeted normothermia.","Death from any cause at 6 months","465 of 925 patients (50%) in the hypothermia group had died, as compared with 446 of 925 (48%) in the normothermia group (relative risk with hypothermia, 1.04; 95% confidence interval [CI], 0.94 to 1.14; P = 0.37)","Open-label trial with blinded assessment of outcomes","Targeted hypothermia at 33degC, followed by controlled rewarming vs. targeted normothermia with early treatment of fever (body temperature, >=37.8degC)","https://pubmed.ncbi.nlm.nih.gov/34133859/?format=pubmed",
"
              
                CRISPR-Cas9 In Vivo Gene Editing for Transthyretin Amyloidosis.
              
            ","NA","Gillmore, Julian D et al.","NEJM","2021/06/26","6 patients","Administration of NTLA-2001 was associated with only mild adverse events and led to decreases in serum TTR protein concentrations through targeted knockout of TTR.","Safety and pharmacodynamic effects of single escalating doses of NTLA-2001","Mean reduction from baseline in serum TTR protein concentration was 52% (range, 47 to 56) in the group that received a dose of 0.1 mg per kilogram and was 87% (range, 80 to 96) in the group that received a dose of 0.3 mg per kilogram.","Not mentioned","0.1 mg per kilogram and 0.3 mg per kilogram","https://pubmed.ncbi.nlm.nih.gov/34215024/?format=pubmed",
"
              
                Effect of Implantable vs Prolonged External Electrocardiographic Monitoring on Atrial Fibrillation Detection in Patients With Ischemic Stroke: The PER DIEM Randomized Clinical Trial.
              
            ","NA","Buck, Brian H et al.","JAMA","2021/06/01","300 patients","Implantable electrocardiographic monitoring for 12 months, compared with prolonged external monitoring for 30 days, resulted in a significantly greater proportion of patients with AF detected over 12 months.","Development of definite AF or highly probable AF (adjudicated new AF lasting >=2 minutes within 12 months of randomization)","15.3% (23/150) of patients in the implantable loop recorder group and 4.7% (7/150) of patients in the external loop recorder group (between-group difference, 10.7% [95% CI, 4.0% to 17.3%]; risk ratio, 3.29 [95% CI, 1.45 to 7.42]; P = .003).","Open-label","Implantable loop recorder (n = 150) vs External loop recorder (n = 150)","https://pubmed.ncbi.nlm.nih.gov/34061146/?format=pubmed",
"
              
                Effect of a Hospital and Postdischarge Quality Improvement Intervention on Clinical Outcomes and Quality of Care for Patients With Heart Failure With Reduced Ejection Fraction: The CONNECT-HF Randomized Clinical Trial.
              
            ","NA","DeVore, Adam D et al.","JAMA","2021/07/27","5647 patients","The intervention did not significantly reduce the time to first heart failure rehospitalization or death, or improve the","Time to first heart failure rehospitalization or death, and change in a composite heart failure quality-of-care score","Heart failure rehospitalization or all-cause mortality occurred in 38.6% in the intervention group vs 39.2% in usual care (adjusted hazard ratio, 0.92 [95% CI, 0.81 to 1.05). The baseline quality-of-care score was 42.1% vs 45.5%, respectively, and the change from baseline to follow-up was 2.3% vs -1.0% (difference, 3.3% [95% CI, -0.8% to 7.3%]), with no significant difference between the 2 groups in the odds of achieving a higher composite quality score at last follow-up (adjusted odds ratio, 1.06 [95% CI, 0.93 to 1.21]).","Not stated","Intervention group vs usual care","https://pubmed.ncbi.nlm.nih.gov/34313687/?format=pubmed",
"
              
                Daratumumab-Based Treatment for Immunoglobulin Light-Chain Amyloidosis.
              
            ","ANDROMEDA","Kastritis, Efstathios et al.","NEJM","2021/06/30","388 patients","The addition of daratumumab to bortezomib, cyclophosphamide, and dexamethasone was associated with higher frequencies of hematologic complete response and survival free from major organ deterioration or hematologic progression in patients with newly diagnosed AL amyloidosis.","Hematologic complete response","53.3% in the daratumumab group vs. 18.1% in the control group (relative risk ratio, 2.9; 95% confidence interval [CI], 2.1 to 4.1; P<0.001).","Not stated","Control group (bortezomib, cyclophosphamide, and dexamethasone) vs. Daratumumab group (bortezomib, cyclophosphamide, and dexamethasone + subcutaneous daratumumab followed by single-agent daratumumab every 4 weeks for up to 24 cycles)","https://pubmed.ncbi.nlm.nih.gov/34192431/?format=pubmed",
"
              
                Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): health status analysis of a randomised, double-blind, placebo-controlled, phase 3 trial.
              
            ","NA","Spertus, John A et al.","Lancet","2021/05/18","251","Mavacamten improved the health status of patients with symptomatic obstructive hypertrophic cardiomyopathy compared","Kansas City Cardiomyopathy Questionnaire (KCCQ)","At 30 weeks, the change in KCCQ-OS score was greater with mavacamten than placebo (mean score 14*9 [SD 15*8] vs 5*4 [13*7]; difference +9*1 [95% CI 5*5-12*8]; p<0*0001), with similar benefits across all KCCQ subscales. The proportion of patients with a very large change (KCCQ-OS >=20 points) was 36% (33 of 92) in the mavacamten group versus 15% (13 of 88) in the placebo group, with an estimated absolute difference of 21% (95% CI 8*8-33*4) and number needed to treat of five (95% CI 3-11).","Both patients and staff were masked to study treatment","Mavacamten vs. Placebo","https://pubmed.ncbi.nlm.nih.gov/34004177/?format=pubmed",
"
              
                Healthy Weight Loss Maintenance with Exercise, Liraglutide, or Both Combined.
              
            ","NA","Lundgren, Julie R et al.","NEJM","2021/05/05","195","Combining exercise and liraglutide therapy improved healthy weight loss maintenance more than either treatment alone.","Change in body weight","-9.5 kg","Not specified","Exercise group, liraglutide group, combination group, placebo group","https://pubmed.ncbi.nlm.nih.gov/33951361/?format=pubmed",
"
              
                Sotatercept for the Treatment of Pulmonary Arterial Hypertension.
              
            ","PULSAR","Humbert, Marc et al.","NEJM","2021/03/31","106","Treatment with sotatercept resulted in a reduction in pulmonary vascular resistance in patients receiving background therapy for pulmonary arterial hypertension.","Change from baseline to week 24 in pulmonary vascular resistance","The least-squares mean difference between the sotatercept 0.3-mg group and the placebo group in the change from baseline to week 24 in pulmonary vascular resistance was -145.8 dyn * sec * cm(-5) (95% CI, -241.0 to -50.6; P = 0.003). The least-squares mean difference between the sotatercept 0.7-mg group and the placebo group was -239.5 dyn * sec * cm(-5) (95% CI, -329.3 to -149.7; P<0.001).","Not specified","Sotatercept 0.3 mg per kilogram of body weight every 3 weeks or 0.7 mg per kilogram every 3 weeks or placebo","https://pubmed.ncbi.nlm.nih.gov/33789009/?format=pubmed",
"
              
                Endovascular Therapy for Stroke Due to Basilar-Artery Occlusion.
              
            ","BASICS","Langezaal, Lucianne C M et al.","NEJM","2021/05/19","300 patients","Endovascular therapy and medical therapy did not differ significantly with respect to a favorable functional outcome, but larger trials are needed to determine the efficacy and safety of endovascular therapy for basilar-artery occlusion.","Favorable functional outcome, defined as a score of 0 to 3 on the modified Rankin scale","68 of 154 patients (44.2%) in the endovascular group and 55 of 146 patients (37.7%) in the medical care group (risk ratio, 1.18; 95% CI, 0.92 to 1.50).","Not specified","Endovascular therapy group and standard medical care group","https://pubmed.ncbi.nlm.nih.gov/34010530/?format=pubmed",
"
              
                Effect of Long-term Continuous Cardiac Monitoring vs Usual Care on Detection of Atrial Fibrillation in Patients With Stroke Attributed to Large- or Small-Vessel Disease: The STROKE-AF Randomized Clinical Trial.
              
            ","STROKE-AF","Bernstein, Richard A et al.","JAMA","2021/06/01","496","Monitoring with an ICM compared with usual care detected significantly more AF over 12 months in patients with stroke attributed to large- or small-vessel disease.","Incident AF lasting more than 30 seconds through 12 months","AF detection at 12 months was significantly higher in the ICM group vs the control group (27 patients [12.1%] vs 4 patients [1.8%]; hazard ratio, 7.4 [95% CI, 2.6-21.3]; P < .001)","Not specified","Intervention group (n = 242) and control group (n = 250)","https://pubmed.ncbi.nlm.nih.gov/34061145/?format=pubmed",
"
              
                Safety and Efficacy of Vadadustat for Anemia in Patients Undergoing Dialysis.
              
            ","NA","Eckardt, Kai-Uwe et al.","NEJM","2021/04/29","3923","Vadadustat was noninferior to darbepoetin alfa with respect to cardiovascular safety and correction and maintenance of hemoglobin concentrations.","First occurrence of a major adverse cardiovascular event (MACE)","A first MACE occurred in 355 patients (18.2%) in the vadadustat group and in 377 patients (19.3%) in the darbepoetin alfa group (hazard ratio, 0.96; 95% confidence interval [CI], 0.83 to 1.11).","Open-label","Vadadustat and darbepoetin alfa","https://pubmed.ncbi.nlm.nih.gov/33913638/?format=pubmed",
"
              
                Effect of Treating Hyperphosphatemia With Lanthanum Carbonate vs Calcium Carbonate on Cardiovascular Events in Patients With Chronic Kidney Disease Undergoing Hemodialysis: The LANDMARK Randomized Clinical Trial.
              
            ","LANDMARK","Ogata, Hiroaki et al.","JAMA","2021/05/18","2374 patients","Treatment of hyperphosphatemia with lanthanum carbonate compared with calcium carbonate did not result in a significant difference in composite cardiovascular events. However,","Composite cardiovascular event (cardiovascular death, nonfatal myocardial infarction or stroke, unstable angina, transient ischemic attack, or hospitalization for heart failure or ventricular arrhythmia)","Cardiovascular events occurred in 147 of 1063 patients in the lanthanum calcium group and 134 of 1072 patients in the calcium carbonate group (incidence rate, 4.80 vs 4.30 per 100 person-years; difference 0.50 per 100 person-years [95% CI, -0.57 to 1.56]; hazard ratio [HR], 1.11 [95%, CI, 0.88 to 1.41], P = .37).","Blinded end point adjudication","Lanthanum carbonate (n = 1154) vs calcium carbonate (n = 1155)","https://pubmed.ncbi.nlm.nih.gov/34003226/?format=pubmed",
"
              
                Final Report of a Trial of Intensive versus Standard Blood-Pressure Control.
              
            ","SPRINT","Lewis, Cora E et al.","NEJM","2021/05/19","9361 participants","Targeting a systolic blood pressure of less than 120 mm Hg resulted in lower rates of major adverse cardiovascular events and lower all-cause mortality than targeting a systolic blood pressure of less than 140 mm Hg.","Composite of myocardial infarction, other acute coronary syndromes, stroke, acute decompensated heart failure, or death from cardiovascular causes","Rate of the primary outcome, 1.77% per year vs. 2.40% per year; hazard ratio, 0.73; 95% confidence interval [CI], 0.63 to 0.86; all-cause mortality, 1.06% per year vs. 1.41% per year; hazard ratio, 0.75; 95% CI, 0.61 to 0.92","Not stated","Intensive treatment target (systolic blood pressure, <120 mm Hg) vs. Standard treatment target (systolic blood pressure, <140 mm Hg)","https://pubmed.ncbi.nlm.nih.gov/34010531/?format=pubmed",
"
              
                Inhaled Treprostinil in Pulmonary Hypertension Due to Interstitial Lung Disease.
              
            ","NA","Waxman, Aaron et al.","NEJM","2021/01/13","326","Inhalation of treprostinil improved exercise capacity in patients with pulmonary hypertension due to interstitial lung disease compared to placebo.","Difference between the two groups in the change in peak 6-minute walk distance from baseline to week 16","Least-squares mean difference between the treprostinil group and the placebo group in the change from baseline in the 6-minute walk distance was 31.12 m (95% confidence interval [CI], 16.85 to 45.39; P<0.001).","Double-blind","Treprostinil vs. Placebo","https://pubmed.ncbi.nlm.nih.gov/33440084/?format=pubmed",
"
              
                Effect of Marine Omega-3 Fatty Acid and Vitamin D Supplementation on Incident Atrial Fibrillation: A Randomized Clinical Trial.
              
            ","NA","Albert, Christine M et al.","JAMA","2021/03/16","25,119","Treatment with EPA-DHA or vitamin D3, compared with placebo, resulted in no significant difference in the risk of incident AF over a median follow-up of more than 5 years. The findings do not support the use of either agent for the primary prevention of incident AF.","Incident AF confirmed by medical record review","Incident AF events occurred in 469 (3.7%) vs 431 (3.4%) participants, respectively (hazard ratio, 1.09; 95% CI, 0.96-1.24; P = .19)","Yes","EPA-DHA and vitamin D3 vs placebo","https://pubmed.ncbi.nlm.nih.gov/33724323/?format=pubmed",
"
              
                Transdermal oestradiol for androgen suppression in prostate cancer: long-term cardiovascular outcomes from the randomised Prostate Adenocarcinoma Transcutaneous Hormone (PATCH) trial programme.
              
            ","NA","Langley, Ruth E et al.","Lancet","2021/02/14","1694","Oestrogens administered transdermally should be reconsidered for androgen suppression in the management of prostate cancer.","Cardiovascular morbidity and mortality","The time to first cardiovascular event did not differ between treatments (hazard ratio 1*11, 95% CI 0*80-1*53; p=0*54 [including sudden deaths without post-mortem report]; 1*20, 0*86-1*68; p=0*29 [confirmed group only]).","Not stated","LHRHa (n=790) or tE2 patches (n=904)","https://pubmed.ncbi.nlm.nih.gov/33581820/?format=pubmed",
"
              
                Polypill with or without Aspirin in Persons without Cardiovascular Disease.
              
            ","International Polycap Study 3 Investigators","Yusuf, Salim et al.","NEJM","2020/11/13","5713 participants","Error","Death from cardiovascular causes, myocardial infarction, stroke, resuscitated cardiac arrest, heart failure, or revascularization for the polypill comparison and death from cardiovascular causes, myocardial infarction, or stroke for the aspirin comparison","For the polypill comparison, the primary outcome occurred in 126 participants (4.4%) in the polypill group and in 157 (5.5%) in the placebo group (hazard ratio, 0.79; 95% CI, 0.63 to 1.00). For the aspirin comparison, the primary outcome occurred in 116 participants (4.1%) in the aspirin group and in 134 (4.7%) in the placebo group (hazard ratio, 0.86; 95% CI, 0.67 to 1.10). For the polypill-plus-aspirin comparison, the primary outcome occurred in 59 participants (4.1%) in the combined-treatment group","Yes","Polypill group vs. placebo group, aspirin group vs. placebo group, polypill plus aspirin group vs. double placebo group","https://pubmed.ncbi.nlm.nih.gov/33186492/?format=pubmed",
"
              
                First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial.
              
            ","NA","Baas, Paul et al.","Lancet","2021/01/24","713 patients","Nivolumab plus ipilimumab significantly improved overall survival compared to chemotherapy, with 2-year overall survival rates of 41% in the nivolumab plus ipilimumab group and 27% in the chemotherapy group.","Overall survival","Median overall survival 18.1 months (95% CI 16.8-21.4) in the nivolumab plus ipilimumab group vs. 14.1 months (12.4-16.2) in the chemotherapy group; hazard ratio 0.74 (96.6% CI 0.60-0.91); p=0.0020; 2-year overall survival rates were 41% (95% CI 35.1-46.5) in the nivolumab plus ipilimumab group and 27% (21.9-32.4) in the chemotherapy group.","Open-label","nivolumab plus ipilimumab vs. platinum plus pemetrexed chemotherapy","https://pubmed.ncbi.nlm.nih.gov/33485464/?format=pubmed",
"
              
                Effect of High-Intensity Interval Training, Moderate Continuous Training, or Guideline-Based Physical Activity Advice on Peak Oxygen Consumption in Patients With Heart Failure With Preserved Ejection Fraction: A Randomized Clinical Trial.
              
            ","OptimEx-Clin Study Group","Mueller, Stephan et al.","JAMA","2021/02/09","180","High-intensity interval training and moderate continuous training did not have a statistically significant effect on peak V","Change in peak Vo2 after 3 months","Change in peak Vo2 over 3 months for high-intensity interval training vs guideline control was 1.1 vs -0.6 mL/kg/min (difference, 1.5 [95% CI, 0.4 to 2.7]); for moderate continuous training vs guideline control, 1.6 vs -0.6 mL/kg/min (difference, 2.0 [95% CI, 0.9 to 3.1]); and for high-intensity interval training vs moderate continuous training, 1.1 vs 1.6 mL/kg/min (difference, -0.4 [95% CI, -1.4 to 0.6]).","Outcomes were analyzed by core laboratories blinded to treatment groups; however, the patients and staff conducting the evaluations were not blinded.","High-intensity interval training, moderate continuous training, and guideline-based advice on physical activity","https://pubmed.ncbi.nlm.nih.gov/33560320/?format=pubmed",
"
              
                Discontinuing b-lactam treatment after 3 days for patients with community-acquired pneumonia in non-critical care wards (PTC): a double-blind, randomised, placebo-controlled, non-inferiority trial.
              
            ","(PTC)","Dinh, Aurelien et al.","Lancet","2021/03/28","706","Discontinuing b-lactam treatment after 3 days was non-inferior to 8 days of treatment for patients admitted to hospital with community-acquired pneumonia who met clinical stability criteria, which could allow substantial reduction of antibiotic consumption.","Cure 15 days after first antibiotic intake, defined by apyrexia (temperature <=37*8degC), resolution or improvement of respiratory symptoms, and no additional antibiotic treatment for any cause","In the ITT analysis, cure at day 15 occurred in 117 (77%) of 152 participants in the placebo group and 102 (68%) of 151 participants in the b-lactam group (between-group difference of 9*42%, 95% CI -0*38 to 20*04), indicating non-inferiority.","Participants, clinicians, and study staff were masked to treatment allocation","Placebo group and b-lactam treatment group","https://pubmed.ncbi.nlm.nih.gov/33773631/?format=pubmed",
"
              
                Sotagliflozin in Patients with Diabetes and Chronic Kidney Disease.
              
            ","SCORED","Bhatt, Deepak L et al.","NEJM","2020/11/17","10,584","Sotagliflozin resulted in a lower risk of the composite of deaths from cardiovascular causes, hospitalizations for heart failure, and urgent visits for heart failure than placebo, but was associated with adverse events.","Composite of the total number of deaths from cardiovascular causes, hospitalizations for heart failure, and urgent visits for heart failure","Hazard ratio, 0.74; 95% confidence interval [CI], 0.63 to 0.88; P<0.001","Double-blind","Sotagliflozin vs. Placebo","https://pubmed.ncbi.nlm.nih.gov/33200891/?format=pubmed",
"
              
                Dipeptidyl Peptidase 4 Inhibition for Prophylaxis of Acute Graft-versus-Host Disease.
              
            ","NA","Farag, Sherif S et al.","NEJM","2021/01/06","36 patients","In this study, sitagliptin in combination with tacrolimus and sirolimus resulted in a low incidence of grade II to IV acute GVHD by day 100 after myeloablative allogeneic hematopoietic stem-cell transplantation.","Incidence of grade II to IV acute GVHD","Incidence of grade II to IV acute GVHD was 5% (95% confidence interval [CI], 1 to 16), and the incidence of grade III or IV GVHD was 3% (95% CI, 0 to 12).","Not specified","Patients receiving myeloablative conditioning followed by mobilized peripheral-blood stem-cell transplants","https://pubmed.ncbi.nlm.nih.gov/33406328/?format=pubmed",
"
              
                Cardiac Myosin Activation with Omecamtiv Mecarbil in Systolic Heart Failure.
              
            ","GALACTIC-HF","Teerlink, John R et al.","NEJM","2020/11/13","8256 patients","Omecamtiv mecarbil was associated with a lower incidence of a composite of a heart-failure event or death from cardiovascular causes than placebo.","Composite of a first heart-failure event (hospitalization or urgent visit for heart failure) or death from cardiovascular causes","1523 of 4120 patients (37.0%) in the omecamtiv mecarbil group and in 1607 of 4112 patients (39.1%) in the placebo group (hazard ratio, 0.92; 95% confidence interval [CI], 0.86 to 0.99; P = 0.03).","Unknown","omecamtiv mecarbil vs. placebo","https://pubmed.ncbi.nlm.nih.gov/33185990/?format=pubmed",
"
              
                Sotagliflozin in Patients with Diabetes and Recent Worsening Heart Failure.
              
            ","SOLOIST-WHF","Bhatt, Deepak L et al.","NEJM","2020/11/17","1222 patients","Sotagliflozin therapy, initiated before or shortly after discharge, resulted in a significantly lower total number of deaths from cardiovascular causes and hospitalizations and urgent visits for heart failure than placebo.","Total number of deaths from cardiovascular causes and hospitalizations and urgent visits for heart failure (first and subsequent events)","The rate (the number of events per 100 patient-years) of primary end-point events was lower in the sotagliflozin group than in the placebo group (51.0 vs. 76.3; hazard ratio, 0.67; 95% confidence interval [CI], 0.52 to 0.85; P<0.001).","Double-blind","Sotagliflozin group and placebo group","https://pubmed.ncbi.nlm.nih.gov/33200892/?format=pubmed",
"
              
                Effect of Discontinuing vs Continuing Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers on Days Alive and Out of the Hospital in Patients Admitted With COVID-19: A Randomized Clinical Trial.
              
            ","BRACE","Lopes, Renato D et al.","JAMA","2021/01/19","659 patients","These findings do not support routinely discontinuing ACEIs or ARBs among patients hospitalized with mild to moderate COVID-19 if there is an indication for treatment.","Number of days alive and out of the hospital through 30 days","There was no significant difference in the number of days alive and out of the hospital in patients in the discontinuation group (mean, 21.9 days [SD, 8 days]) vs patients in the continuation group (mean, 22.9 days [SD, 7.1 days]) and the mean ratio was 0.95 (95% CI, 0.90-1.01).","Unknown","Discontinuation (n = 334) or continuation (n = 325) of ACEIs or ARBs","https://pubmed.ncbi.nlm.nih.gov/33464336/?format=pubmed",
"
              
                Effect of Out-of-Hospital Sodium Nitrite on Survival to Hospital Admission After Cardiac Arrest: A Randomized Clinical Trial.
              
            ","NA","Kim, Francis et al.","JAMA","2021/01/12","1502 adults","Administration of sodium nitrite, compared with placebo, did not significantly improve survival to hospital admission. These findings do not support the use of sodium nitrite during resuscitation from out-of-hospital cardiac arrest.","Survival to hospital admission","205 patients (41%) in the 45 mg of sodium nitrite group and 212 patients (43%) in the 60 mg of sodium nitrite group compared with 218 patients (44%) in the placebo group; the mean difference for the 45-mg dose vs placebo was -2.9% (1-sided 95% CI, -8.0% to ; P = .82) and the mean difference for the 60-mg dose vs placebo was -1.3% (1-sided 95% CI, -6.5% to ; P = .66).","Double-blind, placebo-controlled","45 mg of sodium nitrite, 60 mg of sodium nitrite, and placebo","https://pubmed.ncbi.nlm.nih.gov/33433575/?format=pubmed",
"
              
                Effect of High-Dose Trivalent vs Standard-Dose Quadrivalent Influenza Vaccine on Mortality or Cardiopulmonary Hospitalization in Patients With High-risk Cardiovascular Disease: A Randomized Clinical Trial.
              
            ","INVESTED","Vardeny, Orly et al.","JAMA","2020/12/04","5260 participants","High-dose trival","Time to the composite of all-cause death or cardiopulmonary hospitalization during each enrolling season","In the high-dose trivalent vaccine group, there were 975 primary outcome events (883 hospitalizations for cardiovascular or pulmonary causes and 92 deaths from any cause) among 884 participants during 3577 participant-seasons (event rate, 45 per 100 patient-years), whereas in the standard-dose quadrivalent vaccine group, there were 924 primary outcome events (846 hospitalizations for cardiovascular or pulmonary causes and 78 deaths from any cause) among 837 participants during 3577 participant-seasons (event rate, 42 per 100 patient-years) (hazard ratio, 1.06 [95% CI, 0.97-1.17]; P = .21).","Double-blind","High-dose trivalent (n = 2630) vs standard-dose quadrivalent (n = 2630) inactivated influenza vaccine","https://pubmed.ncbi.nlm.nih.gov/33275134/?format=pubmed",
